Influenza vaccination in patients with end-stage renal disease: systematic review and assessment of quality of evidence related to vaccine efficacy, effectiveness, and safety

BMC Medicine

Thomas Harder¹  Ole Wichmann¹  Cornelius Remschmidt¹ 

[1] Robert Koch Institute, Immunization Unit, Seestrasse 10, Berlin, 13353, Germany

关键词: Vaccine;    Systematic review;    Influenza;    GRADE;    End-stage renal disease;    Effectiveness;    Dialysis;   

Others  :  1109896
DOI  :  10.1186/s12916-014-0244-9

 received in 2014-09-08, accepted in 2014-11-24,  发布年份 2014

【 摘 要 】

Background

Vaccination against influenza is recommended in patients with end-stage renal disease (ESRD). However, so far, no systematic review has summarized the available evidence on the effectiveness and safety of influenza vaccination in this patient group.

Methods

We conducted a systematic review and meta-analysis and assessed the quality of evidence using the GRADE methodology. We searched MEDLINE, EMBASE, Cochrane Library databases, ClinicalTrials.gov, and reference lists for studies on efficacy, effectiveness, and/or safety of seasonal influenza vaccination in patients with ESRD receiving dialysis. All reported clinical outcomes were considered, including all-cause mortality, cardiac death, infectious death, all-cause hospitalization, hospitalization due to influenza or pneumonia, hospitalization due to bacteremia, viremia, or septicemia, hospitalization due to respiratory infection, ICU admission, and influenza-like illness.

Results

Five observational studies and no randomized-controlled trial were identified. In four studies, risk of bias was high regarding all reported outcomes. Strong residual confounding was likely to be present in one study reporting on three outcomes, as indicated by significant protective effects of vaccination outside influenza seasons. Therefore, the statistically significant protective effects on all-cause mortality (vaccine effectiveness (VE), 32%; 95% CI, 24–39%), cardiac death (VE, 16%; 95% CI, 1–29%), hospitalization due to influenza or pneumonia (VE, 14%; 95% CI, 7–20%), ICU admission (VE, 81%; 95% CI, 63–86%), and influenza-like illness (VE, 12%; 95% CI, 10–14%) have to be taken with caution. According to GRADE, the quality of the body of evidence was considered very low for all outcomes. No study reported on laboratory-confirmed influenza virus infections or on safety endpoints.

Conclusions

Evidence on the protective effects of influenza vaccination in patients with ESRD is limited and of very low quality. Since VE estimates in the available literature are prone to unmeasured confounding, studies using randomization or quasi-experimental designs are needed to determine the extent by which vaccination prevents influenza and related clinical outcomes in this at-risk population. However, given the high rates of health-endangering events in these patients, even a low VE can be considered as sufficient to recommend annual influenza vaccination.

【 授权许可】

   
2014 Remschmidt et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Anand S, Bitton A, Gaziano T: The gap between estimated incidence of end-stage renal disease and use of therapy. PLoS One 2013, 8:e72860.
• [2]U.S. Renal Data System: USRDS 2012 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2013.
• [3]White SL, Chadban SJ, Jan S, Chapman JR, Cass A: How can we achieve global equity in provision of renal replacement therapy? Bull World Health Organ 2008, 86:229-237.
• [4]Descamps-Latscha B: The immune system in end-stage renal disease. Curr Opin Nephrol Hypertens 1993, 2:883-891.
• [5]Hauser AB, Stinghen AE, Kato S, Bucharles S, Aita C, Yuzawa Y, Pecoits-Filho R: Characteristics and causes of immune dysfunction related to uremia and dialysis. Perit Dial Int 2008, 28:S183-S187.
• [6]Kato S, Chmielewski M, Honda H, Pecoits-Filho R, Matsuo S, Yuzawa Y, Tranaeus A, Stenvinkel P, Lindholm B: Aspects of immune dysfunction in end-stage renal disease. Clin J Am Soc Nephrol 2008, 3:1526-1533.
• [7]Naqvi SB, Collins AJ: Infectious complications in chronic kidney disease. Adv Chronic Kidney Dis 2006, 13:199-204.
• [8]Sarnak MJ, Jaber BL: Mortality caused by sepsis in patients with end-stage renal disease compared with the general population. Kidney Int 2000, 58:1758-1764.
• [9]Sarnak MJ, Jaber BL: Pulmonary infectious mortality among patients with end-stage renal disease. Chest 2001, 120:1883-1887.
• [10]Centers for Disease Control and Prevention (CDC): Prevention and control of seasonal influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices--United States, 2013–2014 MMWR Recomm Rep 2013, 62:1-43.
• [11]Public Health England: Chapter 19: Influenza. In The Green Book; 2013. Updated 11 September 2013. [https://www.gov.uk/government/publications/influenza-the-green-book-chapter-19]. Accessed on 20 March 2014
• [12]National Advisory Committee on Immunization (NACI): Statement on Seasonal Influenza Vaccine for 2013–2014. In Canada Communicable Disease Report. October 2013, Volume 39, ACS-4; 2013. [http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/13vol39/acs-dcc-4/index-eng.php]. Accessed on 19 March, 2014.
• [13]German Standing Committee on Vaccination (STIKO): Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut/Stand: August 2013. In Epidemiologisches Bulletin 34/2013; 2013. [http://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2013/Ausgaben/34_13.pdf?__blob=publicationFile]. Accessed on 19 March 2014
• [14]Mastalerz-Migas A, Steciwko A, Brydak LB: Immune response to influenza vaccine in hemodialysis patients with chronic renal failure. Adv Exp Med Biol 2013, 756:285-290.
• [15]Vogtlander NP, Brown A, Valentijn RM, Rimmelzwaan GF, Osterhaus AD: Impaired response rates, but satisfying protection rates to influenza vaccination in dialysis patients. Vaccine 2004, 22:2199-2201.
• [16]Scharpe J, Peetermans WE, Vanwalleghem J, Maes B, Bammens B, Claes K, Osterhaus AD, Vanrenterghem Y, Evenepoel P: Immunogenicity of a standard trivalent influenza vaccine in patients on long-term hemodialysis: an open-label trial. Am J Kidney Dis 2009, 54:77-85.
• [17]Remschmidt C, Wichmann O, Harder T: Methodological quality of systematic reviews on influenza vaccination. Vaccine 2014, 32:1678-1684.
• [18]Moher D, Liberati A, Tetzlaff J, Altman DG, Group P: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009, 151:264-269. W264
• [19]CASP UK: Critical Appraisal Skills Programme (CASP) 2014. CASP Checklists, Oxford; 2014.
• [20]Higgins J, Green S: Cochrane Handbook of Systematic Reviews of Interventions. Cochrane Collaboration; 2011
• [21]Guyatt GH, Oxman AD, Schunemann HJ, Tugwell P, Knottnerus A: GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol 2011, 64:380-382.
• [22]Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schunemann HJ, Group GW: GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008, 336:924-926.
• [23]Wang IK, Lin CL, Lin PC, Liang CC, Liu YL, Chang CT, Yen TH, Morisky DE, Huang CC, Sung FC: Effectiveness of influenza vaccination in patients with end-stage renal disease receiving hemodialysis: a population-based study. PLoS One 2013, 8:e58317.
• [24]Gilbertson DT, Unruh M, McBean AM, Kausz AT, Snyder JJ, Collins AJ: Influenza vaccine delivery and effectiveness in end-stage renal disease. Kidney Int 2003, 63:738-743.
• [25]Bond TC, Spaulding AC, Krisher J, McClellan W: Mortality of dialysis patients according to influenza and pneumococcal vaccination status. Am J Kidney Dis 2012, 60:959-965.
• [26]McGrath LJ, Kshirsagar AV, Cole SR, Wang L, Weber DJ, Sturmer T, Brookhart MA: Influenza vaccine effectiveness in patients on hemodialysis: an analysis of a natural experiment. Arch Intern Med 2012, 172:548-554.
• [27]Slinin Y, Foley RN, Collins AJ: Clinical epidemiology of pneumonia in hemodialysis patients: the USRDS waves 1, 3, and 4 study. Kidney Int 2006, 70:1135-1141.
• [28]Centers for Disease C, Prevention: Update: influenza activity--United States and worldwide, 1997–98 season, and composition of the 1998–99 influenza vaccine MMWR Morb Mortal Wkly Rep 1998, 47:280-284.
• [29]Centers for Disease C, Prevention: Update: influenza activity--United States, 1997–98 season MMWR Morb Mortal Wkly Rep 1998, 47:196-200.
• [30]European Medicines Agency: Explanatory Note on the Withdrawal of the Note for Guidance on Harmonisation of Requirements for Influenza Vaccines and of the Core SmPC/PL for Inactivated Seasonal Influenza Vaccines; 2014. [http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/07/WC500170300.pdf]. Accessed on 6 June, 2014.
• [31]Reber A, Katz J: Immunological assessment of influenza vaccines and immune correlates of protection. Expert Rev Vaccines 2013, 12:519-536.
• [32]Beyer WE: Heterogeneity of case definitions used in vaccine effectiveness studies–and its impact on meta-analysis. Vaccine 2006, 24:6602-6604.
• [33]Lau D, Eurich DT, Majumdar SR, Katz A, Johnson JA: Effectiveness of influenza vaccination in working-age adults with diabetes: a population-based cohort study. Thorax 2013, 68:658-663.
• [34]Jackson ML, Yu O, Nelson JC, Naleway A, Belongia EA, Baxter R, Narwaney K, Jacobsen SJ, Shay DK, Jackson LA: Further evidence for bias in observational studies of influenza vaccine effectiveness: the 2009 influenza A(H1N1) pandemic. Am J Epidemiol 2013, 178:1327-1336.
• [35]Wong K, Campitelli MA, Stukel TA, Kwong JC: Estimating influenza vaccine effectiveness in community-dwelling elderly patients using the instrumental variable analysis method. Arch Intern Med 2012, 172:484-491.
• [36]Demicheli V, Jefferson T, Al-Ansary LA, Ferroni E, Rivetti A, Di Pietrantonj C: Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2014., 3
• [37]Jefferson T, Di Pietrantonj C, Al-Ansary LA, Ferroni E, Thorning S, Thomas RE: Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev 2010., 2
• [38]Evison J, Farese S, Seitz M, Uehlinger DE, Furrer H, Muhlemann K: Randomized, double-blind comparative trial of subunit and virosomal influenza vaccines for immunocompromised patients. Clin Infect Dis 2009, 48:1402-1412.
• [39]Brydak LB, Roszkowska-Blaim M, Machala M, Leszczynska B, Sieniawska M: Antibody response to influenza immunization in two consecutive epidemic seasons in patients with renal diseases. Vaccine 2000, 18:3280-3286.
• [40]Tanzi E, Amendola A, Pariani E, Zappa A, Colzani D, Logias F, Perego A, Zanetti AR: Lack of effect of a booster dose of influenza vaccine in hemodialysis patients. J Med Virol 2007, 79:1176-1179.
• [41]Nikoskelainen J, Vaananen P, Forsstrom J, Kasanen A: Influenza vaccination in patients with chronic renal failure. Scand J Infect Dis 1982, 14:245-251.
• [42]Cavdar C, Sayan M, Sifil A, Artuk C, Yilmaz N, Bahar H, Camsari T: The comparison of antibody response to influenza vaccination in continuous ambulatory peritoneal dialysis, hemodialysis and renal transplantation patients. Scand J Urol Nephrol 2003, 37:71-76.